Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And I forgot to add to my previous post that if the patent extension is granted, and for the thought discussed in that post, presumably, HALO would have a much stronger bargaining position, and that may also be what they may be waiting for.
My thought is that if a potential licensee knows that the patent expires in 2027, they may wait to strike a better deal then with either HALO or a competitor. On the other hand, if a potential licensee knows the patent won’t expire until 2031, that may be too long to wait.
Apparently, they recently received a patent extension from European Union. Supposedly, the U.S. is to act soon on the same extension. That’s all I know.
2 things. First, why don’t you respond to my 9/22 post. Second, I find the AI generated analysis over the top wordy and it added nothing except what has already been hashed out about HALO over and over again if you read analysts’ reports. However, thanks for posting since it’s fascinating to see what AI can do.
Also, could the extension of the Enhanze patent play into this?
Yes, I remember HTI. I first got involved shortly after HALO went public at $4/sh. Apparently, some of the seed money investors wanted management to pump the stock so they could make lots of money. Management refused. So they dumped their stock and I bought my first shares at $1.59.
Just wanted to add to the other post’s concerning the quality and quantity of information on this Board. I’ve been reading this Board since it was established many years ago when the Yahoo Finance Board deteriorated. I learn a lot on this Board from the named posters. So thanks to all of them.
Ok, thanks for the explanation. HALO, unlike those other companies, has earned the right to be the darling of social media!!
Sorry, but I don’t understand your comment.
I just noticed that the most currently reported short interest was up substantially. I guess that might be why the stock has struggled despite all the good news. But I can’t understand why there would be so much short selling when there has been nothing but good news. They might find out soon that that was not such a good move.
Agree.
That’s a good question. I wish I knew. Perhaps management will shed some light on that in the upcoming earnings call. I think Helen said during the recent investor call that she would not address new deals during that call (just focus on patent issue) and would talk about new deals during the earnings call.
Yes, I’m concerned. But I believe that when you have the best subcu product out there, and will be the best for many years to come, and when subcu is becoming more and more important to the healthcare system, I believe the deals will come.
How do you know that they are unable to foster new deals? Just because it’s taking longer than we would all like?
All I can say is that since the beginning of the year there have been 5,6, or 7 very positive announcements. And it’s only January. I’ll let those positive events speak for themselves. The company is doing great.
By the way, I don’t consider telling someone that they are bellyaching a personal attack, but if you take it that way, I apologize.
I repeat my post of 2 weeks ago: “Wednesday, 01/17/2024 11:28:29 AM
Why does someone with continual negative views of this company stick around for so long? Could it be that they know there is so much untapped value and they want to be around to cash in?”
Nothing but bellyaching from your two.
Why does someone with continual negative views of this company stick around for so long? Could it be that they know there is so much untapped value and they want to be around to cash in?
Well, let’s hope that management and the Board read the messages on this Board!! Happy holidays and New Year to all.
I, for one, think that Helen Torley is a very good CEO. I know there are many valid reasons for the company being so undervalued and under appreciated, most of which have been said on this board. However, at the risk of oversimplification, and this is something that has already been pointed out on this board, I think the reason is the lack of a strong retail investment community. We know the institutions love HALO, but they hold so much stock, that it allows the limited number of day traders to play the stock. Every time there is positive momentum, they sell, and it has an exaggerated effect on the stock. So, if I have any criticism of Helen, it’s that she hasn’t been able to engender more excitement and awareness of HALO.
While I am not versed in the technical aspects of these trials, from what I read of the excerpt from argenx, they were testing to see if the subcutaneous version of efgartigimod would work for this particular disease. So, to me. It would seem that the problem was with efgartigimod, and not Enhanze because Enhanze is not designed to cure anything and we know it delivers the various drugs effectively because of all the successful trials with so many different types of drugs.
While I am not versed in the technical aspects of these trials, from what I read of the excerpt from argenx, they were testing to see if the subcutaneous version of efgartigimod would work for this particular disease. So, to me. It would seem that the problem was with efgartigimod, and not Enhanze because Enhanze is not designed to cure anything and we know it delivers the various drugs effectively because of all the successful trials with so many different types of drugs.
Unless there’s some negative event, and the company has said nothing, this happens whenever one of the “institutional holders “ decides to sell. The price gain yesterday may have triggered such a sale. And with so little tradable stock, the price change is always exaggerated up or down.
Unless there’s some negative event, and the company has said nothing, this happens whenever one of the “institutional holders “ decides to sell. The price gain yesterday may have triggered such a sale. And with so little tradable stock, the price change is always exaggerated up or down.
That sounds great. Do they know about HALO?
I recall at a recent conference (don't remember which one), Helen was asked about the Merck subcutaneous effort. My recollection is that she said she did not know what they were using, and then she went on, quite confidently, to explain why she was not particularly worried about the potential competition because HALO was so far advanced in subcu and has such a strong safety record, that future converters will want to go the least risky route (or something to that effect).
Thanks Biotechinvestor1. I especially enjoyed your last paragraph!
I don’t understand why you guys are trying to portray a negative view of a really great company. You always knew that their principal product is Enhanze, which has proved to be very successful. There always will be competition, but iif you have the premier product, which HALO does, you can feel confident in your future. Things may not develop as fast as you would like, but good things don’t always happen as fast as you would like. Go back and read the 2nd quarter earnings transcript and refresh your memory on how many good things are going on with the company. On the other hand, if you don’t believe Helen, that’s a different problem.
I would much rather be viewed as a growth stock (which I think HALO is)—higher P/E ratio!
I would much rather be viewed as a growth stock (which I think HALO is)—higher P/E ratio!
Let’s hope!
I would think at least Blackrock and Vanguard have conversations with management on a regular basis. I would hope that at some point they would put pressure on Helen to sell the company so that they can liquidate their investment. How else can they liquidate their investment? You don’t sell 18 million shares on the open market do you?
A related question: Blackrock owns 13 million shares and Vanguard owns 13 million shares—what could they be thinking in terms of their exit strategy?
It's very frustrating to keep waiting. But Helen spoke at 3 conferences last month and reiterated the 3 new deals each time. I can't imagine she would have done this if she didn't have sufficient confidence that they would close this year. HALO management has always been very careful in what they say publicly.
I disagree with you about poor management. I think Helen Torley is doing a very good job of building a strong, profitable company in an important area for patient care. Yes, the stock price movement is very frustrating and has been since the company went public back in 2004. Maybe it’s because so much of the stock is owned by institutions and there are not enough shares being traded on a daily basis which allows for manipulation of the price. I really don’t know, but it’s not due to poor management. If I wanted to complain about Helen, I would say that I wish she could find a way to get more retail investors interested in the company. We know the institutions are interested.
Very encouraging article. Thanks for posting.
I haven’t read their report, but they either have their own agenda, or are unbelievably ignorant of the company they are writing about. And this is Goldman Sachs?!!
I wasn’t able to open the link. Do you have a better connection? Thanks.
Got it. Thanks so much. My gosh, when you look at the information in that presentation, and then you look at the stock price, all you can do is scratch your head!
I looked back at the PR for the guidance for this year and she only referred to one new deal. Where did you find reference to three new deals? Thanks.
Thanks for your encouraging words. I think we all need some of that!